Krystal Biotech (KRYS) Director Daniel Janney Receives Equity Awards

What Happened
Daniel Janney, a member of Krystal Biotech's Board of Directors, was granted equity awards on September 14, 2026: 1,187 stock options and 471 restricted stock units (RSUs). The Form 4 reports these as acquisitions (code A) with a reported price of $0.00 and total reported value of $0 because these are grants (derivative awards) rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-09-14; Form 4 filed 2026-09-16 (appears filed within the standard two‑business‑day window).
• Awards: 1,187 stock options (derivative) and 471 RSUs (derivative).
• Reported price/value: $0.00 per share; $0 total (typical for grant entries).
• Vesting: Options vest in full on September 14, 2027, subject to continued board service and earlier vesting per the company’s Non‑Employee Director Compensation Policy (F1). RSUs vest in full on September 14, 2027 and each RSU represents a contingent right to one share (F2, F3).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Other: No exercise, sale, tax withholding, 10b5‑1 plan, or gift codes noted in the excerpt.

Context
These entries are grants of director compensation (options + RSUs). RSUs convert to shares upon vesting; stock options provide the right to buy shares in the future (exercise terms/strike price not shown in the excerpt). Such awards are routine for non‑employee directors and do not represent an immediate market buy or sell.